{{Rsnum
|rsid=6844110
|Chromosome=4
|position=33727609
|Orientation=plus
|GMAF=0.2668
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 78.8 | 19.5 | 1.8
| HCB | 50.0 | 39.0 | 11.0
| JPT | 46.0 | 44.2 | 9.7
| YRI | 27.2 | 44.9 | 27.9
| ASW | 47.4 | 43.9 | 8.8
| CHB | 50.0 | 39.0 | 11.0
| CHD | 48.1 | 41.5 | 10.4
| GIH | 69.3 | 26.7 | 4.0
| LWK | 30.6 | 47.2 | 22.2
| MEX | 61.4 | 36.8 | 1.8
| MKK | 37.0 | 46.8 | 16.2
| TSI | 80.2 | 17.8 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6844110
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.16, combined P value= 9.36E-05. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470183
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6844110
|overall_frequency_n=33
|overall_frequency_d=126
|overall_frequency=0.261905
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}